<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39272875</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>16</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2072-6694</ISSN><JournalIssue CitedMedium="Print"><Volume>16</Volume><Issue>17</Issue><PubDate><Year>2024</Year><Month>Aug</Month><Day>29</Day></PubDate></JournalIssue><Title>Cancers</Title><ISOAbbreviation>Cancers (Basel)</ISOAbbreviation></Journal><ArticleTitle>A Narrative Review: Repurposing Metformin as a Potential Therapeutic Agent for Oral Cancer.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">3017</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/cancers16173017</ELocationID><Abstract><AbstractText>Oral cancer, particularly oral squamous cell carcinoma (OSCC), is a significant global health challenge because of its high incidence and limited treatment options. Major risk factors, including tobacco use, alcohol consumption, and specific microbiota, contribute to the disease's prevalence. Recently, a compelling association between diabetes mellitus (DM) and oral cancer has been identified, with metformin, a widely used antidiabetic drug, emerging as a potential therapeutic agent across various cancers, including OSCC. This review explores both preclinical and clinical studies to understand the mechanisms by which metformin may exert its anticancer effects, such as inhibiting cancer cell proliferation, inducing apoptosis, and enhancing the efficacy of existing treatments. Preclinical studies demonstrate that metformin modulates crucial metabolic pathways, reduces inflammation, and impacts cellular proliferation, thereby potentially lowering cancer risk and improving patient outcomes. Additionally, metformin's ability to reverse epithelial-to-mesenchymal transition (EMT), regulate the LIN28/let-7 axis, and its therapeutic role in head and neck squamous cell carcinoma (HNSCC) are examined through experimental models. In clinical contexts, metformin shows promise in enhancing therapeutic outcomes and reducing recurrence rates, although challenges such as drug interactions, complex dosing regimens, and risks such as vitamin B12 deficiency remain. Future research should focus on optimizing metformin's application, investigating its synergistic effects with other therapies, and conducting rigorous clinical trials to validate its efficacy in OSCC treatment. This dual exploration underscores metformin's potential to play a transformative role in both diabetes management and cancer care, potentially revolutionizing oral cancer treatment strategies.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Jui-Hsiang</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>Division of Endocrinology and Metabolism, Department of Internal Medicine, Taoyuan General Hospital, Ministry of Health and Welfare, Taoyuan 33004, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hsin</LastName><ForeName>Pei-Yi</ForeName><Initials>PY</Initials><AffiliationInfo><Affiliation>School of Dentistry, College of Oral Medicine, Taipei Medical University, Taipei 11031, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hsiao</LastName><ForeName>Yung-Chia</ForeName><Initials>YC</Initials><AffiliationInfo><Affiliation>School of Dentistry, College of Oral Medicine, Taipei Medical University, Taipei 11031, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Bo-Jun</ForeName><Initials>BJ</Initials><AffiliationInfo><Affiliation>School of Dentistry, College of Oral Medicine, Taipei Medical University, Taipei 11031, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhuang</LastName><ForeName>Zhi-Yun</ForeName><Initials>ZY</Initials><AffiliationInfo><Affiliation>School of Dentistry, College of Oral Medicine, Taipei Medical University, Taipei 11031, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Chiang-Wen</ForeName><Initials>CW</Initials><AffiliationInfo><Affiliation>Department of Nursing, Division of Basic Medical Sciences, Chronic Diseases and Health Promotion Research Center, Chang Gung University of Science and Technology, Chiayi 61363, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Respiratory Care, Chang Gung University of Science and Technology, Chiayi 61363, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Orthopaedic Surgery, Chang Gung Memorial Hospital, Chiayi 61363, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Wei-Ju</ForeName><Initials>WJ</Initials><Identifier Source="ORCID">0000-0003-2824-9572</Identifier><AffiliationInfo><Affiliation>School of Food Safety, College of Nutrition, Taipei Medical University, Taipei 11031, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vo</LastName><ForeName>Thi Thuy Tien</ForeName><Initials>TTT</Initials><AffiliationInfo><Affiliation>Faculty of Dentistry, Nguyen Tat Thanh University, Ho Chi Minh City 700000, Vietnam.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tseng</LastName><ForeName>Chien-Fu</ForeName><Initials>CF</Initials><AffiliationInfo><Affiliation>Graduate Institute of Clinical Dentistry, School of Dentistry, National Taiwan University, Taipei 10048, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Dentistry, Taoyuan General Hospital, Ministry of Health and Welfare, Taoyuan 33004, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tseng</LastName><ForeName>Shih-Fen</ForeName><Initials>SF</Initials><AffiliationInfo><Affiliation>Department of Emergency Medicine, Taoyuan General Hospital, Ministry of Health and Welfare, Taoyuan 33004, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>I-Ta</ForeName><Initials>IT</Initials><Identifier Source="ORCID">0000-0002-8451-0280</Identifier><AffiliationInfo><Affiliation>School of Dentistry, College of Oral Medicine, Taipei Medical University, Taipei 11031, Taiwan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>TMUCOM202405</GrantID><Agency>College of Oral Medicine, Taipei Medical University</Agency><Country /></Grant><Grant><GrantID>ZRRPF6N0011</GrantID><Agency>Chang Gung University of Science Foundation</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>08</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Cancers (Basel)</MedlineTA><NlmUniqueID>101526829</NlmUniqueID><ISSNLinking>2072-6694</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">anticancer properties</Keyword><Keyword MajorTopicYN="N">diabetes mellitus</Keyword><Keyword MajorTopicYN="N">epithelial-to-mesenchymal transition</Keyword><Keyword MajorTopicYN="N">head and neck squamous cell carcinoma</Keyword><Keyword MajorTopicYN="N">metformin</Keyword><Keyword MajorTopicYN="N">oral squamous cell carcinoma</Keyword></KeywordList><CoiStatement>The authors declare that there are no conflicts of interest regarding the publication of this article.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>8</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>14</Day><Hour>10</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>14</Day><Hour>10</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>14</Day><Hour>1</Hour><Minute>4</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>8</Month><Day>29</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39272875</ArticleId><ArticleId IdType="pmc">PMC11394296</ArticleId><ArticleId IdType="doi">10.3390/cancers16173017</ArticleId><ArticleId IdType="pii">cancers16173017</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Chuchueva N., Carta F., Nguyen H.N., Luevano J., Lewis I.A., Rios-Castillo I., Fanos V., King E., Swistushkin V., Reshetov I., et al. Metabolomics of head and neck cancer in biofluids: An integrative systematic review. Metabolomics. 2023;19:77. doi: 10.1007/s11306-023-02038-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11306-023-02038-2</ArticleId><ArticleId IdType="pubmed">37644353</ArticleId></ArticleIdList></Reference><Reference><Citation>Vincent-Chong V.K. Editorial of special issue “Oral cancer: From pathophysiology to novel therapeutic approaches”. Biomedicines. 2023;11:2748. doi: 10.3390/biomedicines11102748.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biomedicines11102748</ArticleId><ArticleId IdType="pmc">PMC10603978</ArticleId><ArticleId IdType="pubmed">37893121</ArticleId></ArticleIdList></Reference><Reference><Citation>Saikia P.J., Pathak L., Mitra S., Das B. The emerging role of oral microbiota in oral cancer initiation, progression and stemness. Front. Immunol. 2023;14:1198269. doi: 10.3389/fimmu.2023.1198269.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2023.1198269</ArticleId><ArticleId IdType="pmc">PMC10639169</ArticleId><ArticleId IdType="pubmed">37954619</ArticleId></ArticleIdList></Reference><Reference><Citation>Remschmidt B., Pau M., Gaessler J., Zemann W., Jakse N., Payer M., Végh D. Diabetes mellitus and oral cancer: A retrospective study from Austria. Anticancer Res. 2022;42:1899–1903. doi: 10.21873/anticanres.15666.</Citation><ArticleIdList><ArticleId IdType="doi">10.21873/anticanres.15666</ArticleId><ArticleId IdType="pubmed">35347008</ArticleId></ArticleIdList></Reference><Reference><Citation>Galal M.A., Al-Rimawi M., Hajeer A., Dahman H., Alouch S., Aljada A. Metformin: A dual-role player in cancer treatment and prevention. Int. J. Mol. Sci. 2024;25:4083. doi: 10.3390/ijms25074083.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms25074083</ArticleId><ArticleId IdType="pmc">PMC11012626</ArticleId><ArticleId IdType="pubmed">38612893</ArticleId></ArticleIdList></Reference><Reference><Citation>Najafi F., Rajati F., Sarokhani D., Bavandpour M., Moradinazar M. The relationship between metformin consumption and cancer risk: An updated umbrella review of systematic reviews and meta-analyses. Int. J. Prev. Med. 2023;14:90.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10580191</ArticleId><ArticleId IdType="pubmed">37854987</ArticleId></ArticleIdList></Reference><Reference><Citation>Li H., Chen Y., Hu L., Yang W., Gao Z., Liu M., Tao H., Li J. Will metformin use lead to a decreased risk of thyroid cancer? A systematic review and meta-analyses. Eur. J. Med. Res. 2023;28:392. doi: 10.1186/s40001-023-01287-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40001-023-01287-0</ArticleId><ArticleId IdType="pmc">PMC10542235</ArticleId><ArticleId IdType="pubmed">37773165</ArticleId></ArticleIdList></Reference><Reference><Citation>Amengual-Cladera E., Morla-Barcelo P.M., Morán-Costoya A., Sastre-Serra J., Pons D.G., Valle A., Roca P., Nadal-Serrano M. Metformin: From diabetes to cancer-unveiling molecular mechanisms and therapeutic strategies. Biology. 2024;13:302. doi: 10.3390/biology13050302.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biology13050302</ArticleId><ArticleId IdType="pmc">PMC11117706</ArticleId><ArticleId IdType="pubmed">38785784</ArticleId></ArticleIdList></Reference><Reference><Citation>Almeida-Nunes D.L., Silvestre R., Dinis-Oliveira R.J., Ricardo S. Enhancing immunotherapy in ovarian cancer: The emerging role of metformin and statins. Int. J. Mol. Sci. 2023;25:323. doi: 10.3390/ijms25010323.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms25010323</ArticleId><ArticleId IdType="pmc">PMC10779012</ArticleId><ArticleId IdType="pubmed">38203494</ArticleId></ArticleIdList></Reference><Reference><Citation>Hua Y., Zheng Y., Yao Y., Jia R., Ge S., Zhuang A. Metformin and cancer hallmarks: Shedding new lights on therapeutic repurposing. J. Transl. Med. 2023;21:403. doi: 10.1186/s12967-023-04263-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12967-023-04263-8</ArticleId><ArticleId IdType="pmc">PMC10286395</ArticleId><ArticleId IdType="pubmed">37344841</ArticleId></ArticleIdList></Reference><Reference><Citation>Mekala M.R., Bangi B.B., Jayalatha N., Lebaka R.R., Nadendla L.K., Ginjupally U. Association of diabetes with oral cancer—An enigmatic correlation. Asian Pac. J. Cancer Prev. 2020;21:809–814. doi: 10.31557/APJCP.2020.21.3.809.</Citation><ArticleIdList><ArticleId IdType="doi">10.31557/APJCP.2020.21.3.809</ArticleId><ArticleId IdType="pmc">PMC7437308</ArticleId><ArticleId IdType="pubmed">32212811</ArticleId></ArticleIdList></Reference><Reference><Citation>Pollak M. The insulin and insulin-like growth factor receptor family in neoplasia: An update. Nat. Rev. Cancer. 2012;12:159–169. doi: 10.1038/nrc3215.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrc3215</ArticleId><ArticleId IdType="pubmed">22337149</ArticleId></ArticleIdList></Reference><Reference><Citation>Wheaton W.W., Weinberg S.E., Hamanaka R.B., Soberanes S., Sullivan L.B., Anso E., Glasauer A., Dufour E., Mutlu G.M., Budigner G.S., et al. Metformin inhibits mitochondrial complex I of cancer cells to reduce tumorigenesis. Elife. 2014;3:e02242. doi: 10.7554/eLife.02242.</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.02242</ArticleId><ArticleId IdType="pmc">PMC4017650</ArticleId><ArticleId IdType="pubmed">24843020</ArticleId></ArticleIdList></Reference><Reference><Citation>Dowling R.J., Goodwin P.J., Stambolic V. Understanding the benefit of metformin use in cancer treatment. BMC Med. 2011;9:33. doi: 10.1186/1741-7015-9-33.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1741-7015-9-33</ArticleId><ArticleId IdType="pmc">PMC3224599</ArticleId><ArticleId IdType="pubmed">21470407</ArticleId></ArticleIdList></Reference><Reference><Citation>Eikawa S., Nishida M., Mizukami S., Yamazaki C., Nakayama E., Udono H. Immune-mediated antitumor effect by type 2 diabetes drug, metformin. Proc. Natl. Acad. Sci. USA. 2015;112:1809–1814. doi: 10.1073/pnas.1417636112.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1417636112</ArticleId><ArticleId IdType="pmc">PMC4330733</ArticleId><ArticleId IdType="pubmed">25624476</ArticleId></ArticleIdList></Reference><Reference><Citation>Broadfield L.A., Saigal A., Szamosi J.C., Hammill J.A., Bezverbnaya K., Wang D., Gautam J., Tsakiridis E.E., Di Pastena F., McNicol J., et al. Metformin-induced reductions in tumor growth involves modulation of the gut microbiome. Mol. Metab. 2022;61:101498. doi: 10.1016/j.molmet.2022.101498.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molmet.2022.101498</ArticleId><ArticleId IdType="pmc">PMC9096669</ArticleId><ArticleId IdType="pubmed">35452877</ArticleId></ArticleIdList></Reference><Reference><Citation>Madiraju A.K., Erion D.M., Rahimi Y., Zhang X.M., Braddock D.T., Albright R.A., Prigaro B.J., Wood J.L., Bhanot S., MacDonald M.J., et al. Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase. Nature. 2014;510:542–546. doi: 10.1038/nature13270.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature13270</ArticleId><ArticleId IdType="pmc">PMC4074244</ArticleId><ArticleId IdType="pubmed">24847880</ArticleId></ArticleIdList></Reference><Reference><Citation>Sadeghi N., Abbruzzese J.L., Yeung S.C., Hassan M., Li D. Metformin use is associated with better survival of diabetic patients with pancreatic cancer. Clin. Cancer Res. 2012;18:2905–2912. doi: 10.1158/1078-0432.CCR-11-2994.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1078-0432.CCR-11-2994</ArticleId><ArticleId IdType="pmc">PMC3381457</ArticleId><ArticleId IdType="pubmed">22465831</ArticleId></ArticleIdList></Reference><Reference><Citation>Bailey C.J. Metformin: Historical overview. Diabetologia. 2017;60:1566–1576. doi: 10.1007/s00125-017-4318-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00125-017-4318-z</ArticleId><ArticleId IdType="pubmed">28776081</ArticleId></ArticleIdList></Reference><Reference><Citation>Orang A., Marri S., McKinnon R.A., Petersen J., Michael M.Z. Restricting colorectal cancer cell metabolism with metformin: An integrated transcriptomics study. Cancers. 2024;16:2055. doi: 10.3390/cancers16112055.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cancers16112055</ArticleId><ArticleId IdType="pmc">PMC11171104</ArticleId><ArticleId IdType="pubmed">38893174</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou G., Myers R., Li Y., Chen Y., Shen X., Fenyk-Melody J., Wu M., Ventre J., Doebber T., Fujii N., et al. Role of AMP-activated protein kinase in mechanism of metformin action. J. Clin. Invest. 2001;108:1167–1174. doi: 10.1172/JCI13505.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI13505</ArticleId><ArticleId IdType="pmc">PMC209533</ArticleId><ArticleId IdType="pubmed">11602624</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonzalez-Lopez C., Wojeck B.S. Role of metformin in the management of type 2 diabetes: Recent advances. Pol. Arch. Intern. Med. 2023;133:16511. doi: 10.20452/pamw.16511.</Citation><ArticleIdList><ArticleId IdType="doi">10.20452/pamw.16511</ArticleId><ArticleId IdType="pubmed">37317976</ArticleId></ArticleIdList></Reference><Reference><Citation>Weinberg Sibony R., Segev O., Dor S., Raz I. Drug therapies for diabetes. Int. J. Mol. Sci. 2023;24:17147. doi: 10.3390/ijms242417147.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms242417147</ArticleId><ArticleId IdType="pmc">PMC10742594</ArticleId><ArticleId IdType="pubmed">38138975</ArticleId></ArticleIdList></Reference><Reference><Citation>Garza-Lombó C., Schroder A., Reyes-Reyes E.M., Franco R. mTOR/AMPK signaling in the brain: Cell metabolism, proteostasis and survival. Curr. Opin. Toxicol. 2018;8:102–110. doi: 10.1016/j.cotox.2018.05.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cotox.2018.05.002</ArticleId><ArticleId IdType="pmc">PMC6223325</ArticleId><ArticleId IdType="pubmed">30417160</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaw R.J., Lamia K.A., Vasquez D., Koo S.H., Bardeesy N., Depinho R.A., Montminy M., Cantley L.C. The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science. 2005;310:1642–1646. doi: 10.1126/science.1120781.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1120781</ArticleId><ArticleId IdType="pmc">PMC3074427</ArticleId><ArticleId IdType="pubmed">16308421</ArticleId></ArticleIdList></Reference><Reference><Citation>Rena G., Hardie D.G., Pearson E.R. The mechanisms of action of metformin. Diabetologia. 2017;60:1577–1585. doi: 10.1007/s00125-017-4342-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00125-017-4342-z</ArticleId><ArticleId IdType="pmc">PMC5552828</ArticleId><ArticleId IdType="pubmed">28776086</ArticleId></ArticleIdList></Reference><Reference><Citation>Hou Y., Yang Z., Xiang B., Liu J., Geng L., Xu D., Zhan M., Xu Y., Zhang B. Metformin is a potential therapeutic for COVID-19/LUAD by regulating glucose metabolism. Sci. Rep. 2024;14:12406. doi: 10.1038/s41598-024-63081-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-024-63081-0</ArticleId><ArticleId IdType="pmc">PMC11137110</ArticleId><ArticleId IdType="pubmed">38811809</ArticleId></ArticleIdList></Reference><Reference><Citation>Olawore O., Turner L.E., Evans M.D., Johnson S.G., Huling J.D., Bramante C.T., Buse J.B., Stürmer T., N3C Consortium Risk of post-acute sequelae of SARS-CoV-2 infection (PASC) among patients with type 2 diabetes mellitus on anti-hyperglycemic medications. Clin. Epidemiol. 2024;16:379–393. doi: 10.2147/CLEP.S458901.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/CLEP.S458901</ArticleId><ArticleId IdType="pmc">PMC11149650</ArticleId><ArticleId IdType="pubmed">38836048</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee H.S., Noh J.Y., Song J.Y., Cheong H.J., Kim W.J. Metformin reduces the risk of developing influenza A virus related cardiovascular disease. Heliyon. 2023;9:e20284. doi: 10.1016/j.heliyon.2023.e20284.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.heliyon.2023.e20284</ArticleId><ArticleId IdType="pmc">PMC10556598</ArticleId><ArticleId IdType="pubmed">37810823</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng L., Deepak R.N.V.K., Wang G., Meng Z., Tao L., Xie M., Chi W., Zhang Y., Yang M., Liao Y., et al. Hepatic mitochondrial NAD + transporter SLC25A47 activates AMPKα mediating lipid metabolism and tumorigenesis. Hepatology. 2023;78:1828–1842. doi: 10.1097/HEP.0000000000000314.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/HEP.0000000000000314</ArticleId><ArticleId IdType="pmc">PMC10653290</ArticleId><ArticleId IdType="pubmed">36804859</ArticleId></ArticleIdList></Reference><Reference><Citation>Sabbar R., Kadhim S.A.A., Fawzi H.A., Flayih A., Mohammad B., Swadi A. Metformin effects on cardiac parameters in non-diabetic Iraqi patients with heart failure and mid-range ejection fraction-a comparative two-arm parallel clinical study. J. Med. Life. 2023;16:1400–1406.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10719796</ArticleId><ArticleId IdType="pubmed">38107711</ArticleId></ArticleIdList></Reference><Reference><Citation>Dutta S., Shah R.B., Singhal S., Dutta S.B., Bansal S., Sinha S., Haque M. Metformin: A review of potential mechanism and therapeutic utility beyond diabetes. Drug Des. Dev. Ther. 2023;17:1907–1932. doi: 10.2147/DDDT.S409373.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/DDDT.S409373</ArticleId><ArticleId IdType="pmc">PMC10312383</ArticleId><ArticleId IdType="pubmed">37397787</ArticleId></ArticleIdList></Reference><Reference><Citation>Kleibert M., Zygmunciak P., Łakomska K., Mila K., Zgliczyński W., Mrozikiewicz-Rakowska B. Insight into the molecular mechanism of diabetic kidney disease and the role of metformin in its pathogenesis. Int. J. Mol. Sci. 2023;24:13038. doi: 10.3390/ijms241713038.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms241713038</ArticleId><ArticleId IdType="pmc">PMC10487922</ArticleId><ArticleId IdType="pubmed">37685845</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahmoud M.M., Rashed L.A., Soliman S.A., Sayed S.M., Kamel O., Kamar S.S., Hussien R.E.S. SGLT-2 inhibitors enhance the effect of metformin to ameliorate hormonal changes and inflammatory markers in a rat PCOS model. Physiol. Rep. 2023;11:e15858. doi: 10.14814/phy2.15858.</Citation><ArticleIdList><ArticleId IdType="doi">10.14814/phy2.15858</ArticleId><ArticleId IdType="pmc">PMC10659952</ArticleId><ArticleId IdType="pubmed">37985173</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao B., Qiao J., Pang Y. Central regulation of PCOS: Abnormal neuronal-reproductive-metabolic circuits in PCOS pathophysiology. Front. Endocrinol. 2021;12:667422. doi: 10.3389/fendo.2021.667422.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fendo.2021.667422</ArticleId><ArticleId IdType="pmc">PMC8194358</ArticleId><ArticleId IdType="pubmed">34122341</ArticleId></ArticleIdList></Reference><Reference><Citation>Legro R.S., Arslanian S.A., Ehrmann D.A., Hoeger K.M., Murad M.H., Pasquali R., Welt C.K., Endocrine Society Diagnosis and treatment of polycystic ovary syndrome: An Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab. 2013;98:4565–4592.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5399492</ArticleId><ArticleId IdType="pubmed">24151290</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheen A.J. SGLT2 inhibitors: Benefit/risk balance. Curr. Diab. Rep. 2016;16:92.</Citation><ArticleIdList><ArticleId IdType="pubmed">27541294</ArticleId></ArticleIdList></Reference><Reference><Citation>Zinman B., Wanner C., Lachin J.M., Fitchett D., Bluhmki E., Hantel S., Mattheus M., Devins T., Johansen O.E., Woerle H.J., et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N. Engl. J. Med. 2015;373:2117–2128. doi: 10.1056/NEJMoa1504720.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1504720</ArticleId><ArticleId IdType="pubmed">26378978</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruderman N.B., Xu X.J., Nelson L., Cacicedo J.M., Saha A.K., Lan F., Ido Y. AMPK and SIRT1: A long-standing partnership? Am. J. Physiol. Endocrinol. Metab. 2010;298:E751–E760.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2853213</ArticleId><ArticleId IdType="pubmed">20103737</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldman J.D. Combination of empagliflozin and metformin therapy: A consideration of its place in type 2 diabetes therapy. Clin. Med. Insights Endocrinol. Diabetes. 2018;11:1179551418786258. doi: 10.1177/1179551418786258.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1179551418786258</ArticleId><ArticleId IdType="pmc">PMC6043932</ArticleId><ArticleId IdType="pubmed">30013414</ArticleId></ArticleIdList></Reference><Reference><Citation>Torunoglu S.T., Zajda A., Tampio J., Markowicz-Piasecka M., Huttunen K.M. Metformin derivatives-Researchers’ friends or foes? Biochem. Pharmacol. 2023;215:115743. doi: 10.1016/j.bcp.2023.115743.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bcp.2023.115743</ArticleId><ArticleId IdType="pubmed">37591450</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahmoudi G., Ehteshaminia Y., Kokhaei P., Jalali S.F., Jadidi-Niaragh F., Pagheh A.S., Enderami S.E., Kenari S.A., Hassannia H. Enhancement of targeted therapy in combination with metformin on human breast cancer cell lines. Cell Commun. Signal. 2024;22:10. doi: 10.1186/s12964-023-01446-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12964-023-01446-0</ArticleId><ArticleId IdType="pmc">PMC10763326</ArticleId><ArticleId IdType="pubmed">38167105</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun L., Xie C., Wang G., Wu Y., Wu Q., Wang X., Liu J., Deng Y., Xia J., Chen B., et al. Gut microbiota and intestinal FXR mediate the clinical benefits of metformin. Nat. Med. 2018;24:1919–1929. doi: 10.1038/s41591-018-0222-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-018-0222-4</ArticleId><ArticleId IdType="pmc">PMC6479226</ArticleId><ArticleId IdType="pubmed">30397356</ArticleId></ArticleIdList></Reference><Reference><Citation>Hammad Uddin M.K., Khan Sadiq M.S., Ahmed A., Khan M., Maniar T., Mateen S.M., Saba B., Kashif S.M., Usman S., Najeeb S., et al. Applications of metformin in dentistry-A review. J. Taibah Univ. Med. Sci. 2023;18:1299–1310. doi: 10.1016/j.jtumed.2023.03.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtumed.2023.03.014</ArticleId><ArticleId IdType="pmc">PMC10239065</ArticleId><ArticleId IdType="pubmed">37275952</ArticleId></ArticleIdList></Reference><Reference><Citation>Gutkind J.S., Molinolo A.A., Wu X., Wang Z., Nachmanson D., Harismendy O., Alexandrov L.B., Wuertz B.R., Ondrey F.G., Laronde D., et al. Inhibition of mTOR signaling and clinical activity of metformin in oral premalignant lesions. JCI Insight. 2021;6:e147096. doi: 10.1172/jci.insight.147096.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.147096</ArticleId><ArticleId IdType="pmc">PMC8492350</ArticleId><ArticleId IdType="pubmed">34255745</ArticleId></ArticleIdList></Reference><Reference><Citation>Curry J.M., Johnson J., Mollaee M., Tassone P., Amin D., Knops A., Whitaker-Menezes D., Mahoney M.G., South A., Rodeck U., et al. Metformin clinical trial in HPV+ and HPV− head and neck squamous cell carcinoma: Impact on cancer cell apoptosis and immune infiltrate. Front. Oncol. 2018;8:436. doi: 10.3389/fonc.2018.00436.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fonc.2018.00436</ArticleId><ArticleId IdType="pmc">PMC6193523</ArticleId><ArticleId IdType="pubmed">30364350</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu H., Huang Y., Huang M., Huang Z., Wang Q., Qing L., Li L., Xu S., Jia B. Current status, opportunities, and challenges of exosomes in oral cancer diagnosis and treatment. Int. J. Nanomed. 2022;17:2679–2705. doi: 10.2147/IJN.S365594.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/IJN.S365594</ArticleId><ArticleId IdType="pmc">PMC9208818</ArticleId><ArticleId IdType="pubmed">35733418</ArticleId></ArticleIdList></Reference><Reference><Citation>Baskar G., Palaniyandi T., Viswanathan S., Wahab M.R.A., Surendran H., Ravi M., Sivaji A., Rajendran B.K., Natarajan S., Govindasamy G. Recent and advanced therapy for oral cancer. Biotechnol. Bioeng. 2023;120:3105–3115. doi: 10.1002/bit.28452.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/bit.28452</ArticleId><ArticleId IdType="pubmed">37243814</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao L., Wu Y., Shan Y., Tan B., Liao J. A review: Potential application and outlook of photothermal therapy in oral cancer treatment. Biomed. Mater. 2022;17:022008. doi: 10.1088/1748-605X/ac5a23.</Citation><ArticleIdList><ArticleId IdType="doi">10.1088/1748-605X/ac5a23</ArticleId><ArticleId IdType="pubmed">35235924</ArticleId></ArticleIdList></Reference><Reference><Citation>Hung M., Almpani K., Thao B., Sudweeks K., Lipsky M.S. Vitamin D in the prevention and treatment of oral cancer: A scoping review. Nutrients. 2023;15:2346. doi: 10.3390/nu15102346.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu15102346</ArticleId><ArticleId IdType="pmc">PMC10222073</ArticleId><ArticleId IdType="pubmed">37242229</ArticleId></ArticleIdList></Reference><Reference><Citation>Umapathy V.R., Natarajan P.M., Swamikannu B. Review of the role of nanotechnology in overcoming the challenges faced in oral cancer diagnosis and treatment. Molecules. 2023;28:5395. doi: 10.3390/molecules28145395.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules28145395</ArticleId><ArticleId IdType="pmc">PMC10385509</ArticleId><ArticleId IdType="pubmed">37513267</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagaraj B.S., Krishnan Namboori P.K., Akey K.S., Sankaran S., Raman R.K., Natarajan J., Selvaraj J. Vitamin D analog calcitriol for breast cancer therapy; an integrated drug discovery approach. J. Biomol. Struct. Dyn. 2023;41:11017–11043.</Citation><ArticleIdList><ArticleId IdType="pubmed">37054526</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y.C., Chiang Y.F., Lin Y.J., Huang K.C., Chen H.Y., Hamdy N.M., Huang T.C., Chang H.Y., Shieh T.M., Huang Y.J., et al. Effect of vitamin D supplementation on primary dysmenorrhea: A systematic review and meta-analysis of randomized clinical trials. Nutrients. 2023;15:2830. doi: 10.3390/nu15132830.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu15132830</ArticleId><ArticleId IdType="pmc">PMC10343446</ArticleId><ArticleId IdType="pubmed">37447156</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanno K., Akutsu T., Ohdaira H., Suzuki Y., Urashima M. Effect of vitamin D supplements on relapse or death in a p53-immunoreactive subgroup with digestive tract cancer: Post hoc analysis of the AMATERASU randomized clinical trial. JAMA Netw. Open. 2023;6:e2328886. doi: 10.1001/jamanetworkopen.2023.28886.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2023.28886</ArticleId><ArticleId IdType="pmc">PMC10445201</ArticleId><ArticleId IdType="pubmed">37606927</ArticleId></ArticleIdList></Reference><Reference><Citation>Patini R., Favetti Giaquinto E., Gioco G., Castagnola R., Perrotti V., Rupe C., Di Gennaro L., Nocca G., Lajolo C. Malnutrition as a risk factor in the development of oral cancer: A systematic literature review and meta-analyses. Nutrients. 2024;16:360. doi: 10.3390/nu16030360.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu16030360</ArticleId><ArticleId IdType="pmc">PMC10856873</ArticleId><ArticleId IdType="pubmed">38337645</ArticleId></ArticleIdList></Reference><Reference><Citation>Krishnan A.V., Feldman D. Mechanisms of the anti-cancer and anti-inflammatory actions of vitamin D. Annu. Rev. Pharmacol. Toxicol. 2011;51:311–336. doi: 10.1146/annurev-pharmtox-010510-100611.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-pharmtox-010510-100611</ArticleId><ArticleId IdType="pubmed">20936945</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi S., Iriarte C. High-dose oral vitamin D: An emerging therapeutic for skin toxicities associated with cancer treatment. J. Am. Acad. Dermatol. 2024;91:596–597. doi: 10.1016/j.jaad.2024.05.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaad.2024.05.027</ArticleId><ArticleId IdType="pubmed">38763290</ArticleId></ArticleIdList></Reference><Reference><Citation>Giovannucci E. Vitamin D and cancer incidence in the Harvard cohorts. Ann. Epidemiol. 2009;19:84–88. doi: 10.1016/j.annepidem.2007.12.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.annepidem.2007.12.002</ArticleId><ArticleId IdType="pubmed">18291673</ArticleId></ArticleIdList></Reference><Reference><Citation>Giovannucci E. The epidemiology of vitamin D and cancer incidence and mortality: A review (United States) Cancer Causes Control. 2005;16:83–95. doi: 10.1007/s10552-004-1661-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10552-004-1661-4</ArticleId><ArticleId IdType="pubmed">15868450</ArticleId></ArticleIdList></Reference><Reference><Citation>Bikle D.D. Vitamin D metabolism, mechanism of action, and clinical applications. Chem. Biol. 2014;21:319–329. doi: 10.1016/j.chembiol.2013.12.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chembiol.2013.12.016</ArticleId><ArticleId IdType="pmc">PMC3968073</ArticleId><ArticleId IdType="pubmed">24529992</ArticleId></ArticleIdList></Reference><Reference><Citation>Trump D.L., Deeb K.K., Johnson C.S. Vitamin D: Considerations in the continued development as an agent for cancer prevention and therapy. Cancer J. 2010;16:1–9. doi: 10.1097/PPO.0b013e3181c51ee6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/PPO.0b013e3181c51ee6</ArticleId><ArticleId IdType="pmc">PMC2857702</ArticleId><ArticleId IdType="pubmed">20164683</ArticleId></ArticleIdList></Reference><Reference><Citation>Grant W.B., Garland C.F. A critical review of studies on vitamin D in relation to colorectal cancer. Nutr. Cancer. 2004;48:115–123. doi: 10.1207/s15327914nc4802_1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1207/s15327914nc4802_1</ArticleId><ArticleId IdType="pubmed">15231446</ArticleId></ArticleIdList></Reference><Reference><Citation>Das S., Bhattacharya K., Blaker J.J., Singha N.K., Mandal M. Beyond traditional therapy: Mucoadhesive polymers as a new frontier in oral cancer management. Biopolymers. 2023;114:e23556. doi: 10.1002/bip.23556.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/bip.23556</ArticleId><ArticleId IdType="pubmed">37341448</ArticleId></ArticleIdList></Reference><Reference><Citation>Sutar K.P., Shirkoli N.S., Sutar P.S., Kurangi B.K., Dandagi P.M., Masareddy R. Current novel drug deliveries for oral cancer: A chronotherapeutic approach. Curr. Drug Deliv. 2023;20:237–249. doi: 10.2174/1567201819666220408094520.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1567201819666220408094520</ArticleId><ArticleId IdType="pubmed">35400343</ArticleId></ArticleIdList></Reference><Reference><Citation>Vyas S., Zaganjor E., Haigis M.C. Mitochondria and cancer. Cell. 2016;166:555–566. doi: 10.1016/j.cell.2016.07.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2016.07.002</ArticleId><ArticleId IdType="pmc">PMC5036969</ArticleId><ArticleId IdType="pubmed">27471965</ArticleId></ArticleIdList></Reference><Reference><Citation>Olmedo I., Martínez D., Carrasco-Rojas J., Jara J.A. Mitochondria in oral cancer stem cells: Unraveling the potential drug targets for new and old drugs. Life Sci. 2023;331:122065. doi: 10.1016/j.lfs.2023.122065.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lfs.2023.122065</ArticleId><ArticleId IdType="pubmed">37659591</ArticleId></ArticleIdList></Reference><Reference><Citation>Zoughaib M., Pashirova T.N., Nikolaeva V., Kamalov M., Nakhmetova F., Salakhieva D.V., Abdullin T.I. Anticancer and chemosensitizing effects of menadione-containing peptide-targeted solid lipid nanoparticles. J. Pharm. Sci. 2024;113:2258–2267. doi: 10.1016/j.xphs.2024.03.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xphs.2024.03.009</ArticleId><ArticleId IdType="pubmed">38508340</ArticleId></ArticleIdList></Reference><Reference><Citation>Dattilo R., Mottini C., Camera E., Lamolinara A., Auslander N., Doglioni G., Muscolini M., Tang W., Planque M., Ercolani C., et al. Pyrvinium pamoate induces death of triple-negative breast cancer stem-like cells and reduces metastases through effects on lipid anabolism. Cancer Res. 2020;80:4087–4102. doi: 10.1158/0008-5472.CAN-19-1184.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/0008-5472.CAN-19-1184</ArticleId><ArticleId IdType="pmc">PMC8808379</ArticleId><ArticleId IdType="pubmed">32718996</ArticleId></ArticleIdList></Reference><Reference><Citation>García-Heredia J.M., Carnero A. Role of mitochondria in cancer stem cell resistance. Cells. 2020;9:1693. doi: 10.3390/cells9071693.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells9071693</ArticleId><ArticleId IdType="pmc">PMC7407626</ArticleId><ArticleId IdType="pubmed">32679735</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickerman B.A., García-Albéniz X., Logan R.W., Denaxas S., Hernán M.A. Evaluating metformin strategies for cancer prevention: A target trial emulation using electronic health eecords. Epidemiology. 2023;34:690–699. doi: 10.1097/EDE.0000000000001626.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/EDE.0000000000001626</ArticleId><ArticleId IdType="pmc">PMC10524586</ArticleId><ArticleId IdType="pubmed">37227368</ArticleId></ArticleIdList></Reference><Reference><Citation>Brannon-Peppas L., Blanchette J.O. Nanoparticle and targeted systems for cancer therapy. Adv. Drug Deliv. Rev. 2004;56:1649–1659. doi: 10.1016/j.addr.2004.02.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.addr.2004.02.014</ArticleId><ArticleId IdType="pubmed">15350294</ArticleId></ArticleIdList></Reference><Reference><Citation>Sledge G.W., Jr., Miller K.D. Exploiting the hallmarks of cancer: The future conquest of breast cancer. Eur. J. Cancer. 2003;39:1668–1675. doi: 10.1016/S0959-8049(03)00273-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0959-8049(03)00273-9</ArticleId><ArticleId IdType="pubmed">12888360</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao W.T., Chang D.M., Lin M.X., Lee J.W., Tung Y.C., Hsiao J.K. Indocyanine-green-loaded liposomes for photodynamic and photothermal therapies: Inducing apoptosis and ferroptosis in cancer cells with implications beyond oral cancer. Pharmaceutics. 2024;16:224. doi: 10.3390/pharmaceutics16020224.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pharmaceutics16020224</ArticleId><ArticleId IdType="pmc">PMC10891763</ArticleId><ArticleId IdType="pubmed">38399278</ArticleId></ArticleIdList></Reference><Reference><Citation>Men C., Zhang Y., Shi P., Tang Z., Cheng X. ανβ3 integrin-targeted ICG-derived probes for imaging-guided surgery and photothermal therapy of oral cancer. Analyst. 2023;148:6334–6340. doi: 10.1039/D3AN01761C.</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/D3AN01761C</ArticleId><ArticleId IdType="pubmed">37947486</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang X., Jain P.K., El-Sayed I.H., El-Sayed M.A. Plasmonic photothermal therapy (PPTT) using gold nanoparticles. Lasers Med. Sci. 2008;23:217–228. doi: 10.1007/s10103-007-0470-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10103-007-0470-x</ArticleId><ArticleId IdType="pubmed">17674122</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang K., Zhang S., Zhang G., Sun X., Lee S.T., Liu Z. Graphene in mice: Ultrahigh in vivo tumor uptake and efficient photothermal therapy. Nano Lett. 2010;10:3318–3323. doi: 10.1021/nl100996u.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/nl100996u</ArticleId><ArticleId IdType="pubmed">20684528</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo X., Facchetti A. The journey of conducting polymers from discovery to application. Nat. Mater. 2020;19:922–928. doi: 10.1038/s41563-020-0778-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41563-020-0778-5</ArticleId><ArticleId IdType="pubmed">32820293</ArticleId></ArticleIdList></Reference><Reference><Citation>Robinson J.T., Tabakman S.M., Liang Y., Wang H., Casalongue H.S., Vinh D., Dai H. Ultrasmall reduced graphene oxide with high near-infrared absorbance for photothermal therapy. J. Am. Chem. Soc. 2011;133:6825–6831. doi: 10.1021/ja2010175.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/ja2010175</ArticleId><ArticleId IdType="pubmed">21476500</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen G., Roy I., Yang C., Prasad P.N. Nanochemistry and nanomedicine for nanoparticle-based diagnostics and therapy. Chem. Rev. 2016;116:2826–2885. doi: 10.1021/acs.chemrev.5b00148.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.chemrev.5b00148</ArticleId><ArticleId IdType="pubmed">26799741</ArticleId></ArticleIdList></Reference><Reference><Citation>Vines J.B., Yoon J.H., Ryu N.E., Lim D.J., Park H. Gold nanoparticles for photothermal cancer therapy. Front. Chem. 2019;7:167. doi: 10.3389/fchem.2019.00167.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fchem.2019.00167</ArticleId><ArticleId IdType="pmc">PMC6460051</ArticleId><ArticleId IdType="pubmed">31024882</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang K., Feng L., Hong H., Cai W., Liu Z. Preparation and functionalization of graphene nanocomposites for biomedical applications. Nat. Protoc. 2013;8:2392–2403. doi: 10.1038/nprot.2013.146.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nprot.2013.146</ArticleId><ArticleId IdType="pmc">PMC3878091</ArticleId><ArticleId IdType="pubmed">24202553</ArticleId></ArticleIdList></Reference><Reference><Citation>Qi K., Sun B., Liu S.Y., Zhang M. Research progress on carbon materials in tumor photothermal therapy. Biomed. Pharmacother. 2023;165:115070. doi: 10.1016/j.biopha.2023.115070.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopha.2023.115070</ArticleId><ArticleId IdType="pubmed">37390711</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu M., Han X., Xiong H., Gao Y., Xu B., Zhu G., Li J. Cancer nanomedicine: Emerging strategies and therapeutic potentials. Molecules. 2023;28:5145. doi: 10.3390/molecules28135145.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules28135145</ArticleId><ArticleId IdType="pmc">PMC10343932</ArticleId><ArticleId IdType="pubmed">37446806</ArticleId></ArticleIdList></Reference><Reference><Citation>Jain R.K., Stylianopoulos T. Delivering nanomedicine to solid tumors. Nat. Rev. Clin. Oncol. 2010;7:653–664. doi: 10.1038/nrclinonc.2010.139.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrclinonc.2010.139</ArticleId><ArticleId IdType="pmc">PMC3065247</ArticleId><ArticleId IdType="pubmed">20838415</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang P., Hu C., Ran W., Meng J., Yin Q., Li Y. Recent progress in light-triggered nanotheranostics for cancer treatment. Theranostics. 2016;6:948–968. doi: 10.7150/thno.15217.</Citation><ArticleIdList><ArticleId IdType="doi">10.7150/thno.15217</ArticleId><ArticleId IdType="pmc">PMC4876621</ArticleId><ArticleId IdType="pubmed">27217830</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J., Zhao J., Qiao X. Research progress of metformin in the treatment of oral squamous cell carcinoma. Endocrinology. 2023;164:bqad139. doi: 10.1210/endocr/bqad139.</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/endocr/bqad139</ArticleId><ArticleId IdType="pubmed">37738154</ArticleId></ArticleIdList></Reference><Reference><Citation>Tseng C.H. Metformin may reduce oral cancer risk in patients with type 2 diabetes. Oncotarget. 2016;7:2000–2008. doi: 10.18632/oncotarget.6626.</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/oncotarget.6626</ArticleId><ArticleId IdType="pmc">PMC4811512</ArticleId><ArticleId IdType="pubmed">26683519</ArticleId></ArticleIdList></Reference><Reference><Citation>Bouland C., Vanden Eynden X., Lalmand M., Buset T., Yanni A., Javadian R., Rodriguez A., Loeb I., Lechien J.R., Journe F., et al. Preventive and therapeutic effect of metformin in head and neck cancer: A concise review. J. Clin. Med. 2023;12:6195. doi: 10.3390/jcm12196195.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm12196195</ArticleId><ArticleId IdType="pmc">PMC10573641</ArticleId><ArticleId IdType="pubmed">37834839</ArticleId></ArticleIdList></Reference><Reference><Citation>Rêgo D.F., Pavan L.M., Elias S.T., De Luca Canto G., Guerra E.N. Effects of metformin on head and neck cancer: A systematic review. Oral Oncol. 2015;51:416–422. doi: 10.1016/j.oraloncology.2015.01.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.oraloncology.2015.01.007</ArticleId><ArticleId IdType="pubmed">25636350</ArticleId></ArticleIdList></Reference><Reference><Citation>Ji M., Lv Y., Chen C., Xing D., Zhou C., Zhao J., Qi Y., Zhang J., Wang Y., Ma X., et al. Metformin inhibits oral squamous cell carcinoma progression through regulating RNA alternative splicing. Life Sci. 2023;315:121274. doi: 10.1016/j.lfs.2022.121274.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lfs.2022.121274</ArticleId><ArticleId IdType="pubmed">36509195</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei J., Huang J., Kuang Y., Li Y., Zhong D., Song J. Metformin inhibits proliferation of oral squamous cell carcinoma cells by suppressing proteolysis of nerve growth factor receptor. Arch. Oral Biol. 2021;121:104971. doi: 10.1016/j.archoralbio.2020.104971.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.archoralbio.2020.104971</ArticleId><ArticleId IdType="pubmed">33220581</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou X., Hao Q., Liao P., Luo S., Zhang M., Hu G., Liu H., Zhang Y., Cao B., Baddoo M., et al. Nerve growth factor receptor negates the tumor suppressor p53 as a feedback regulator. eLife. 2016;5:e15099. doi: 10.7554/eLife.15099.</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.15099</ArticleId><ArticleId IdType="pmc">PMC4943851</ArticleId><ArticleId IdType="pubmed">27282385</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin W., Liu Y., Liu X., Ma X., Sun B., Yu Z. Metformin inhibits epithelial-mesenchymal transition of oral squamous cell carcinoma via the mTOR/HIF-1α/PKM2/STAT3 pathway. Oncol. Lett. 2021;21:31.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7693125</ArticleId><ArticleId IdType="pubmed">33262823</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang Y., Hong W., Wei X. The molecular mechanisms and therapeutic strategies of EMT in tumor progression and metastasis. J. Hematol. Oncol. 2022;15:129. doi: 10.1186/s13045-022-01347-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13045-022-01347-8</ArticleId><ArticleId IdType="pmc">PMC9461252</ArticleId><ArticleId IdType="pubmed">36076302</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao W., Chen C., Zhou J., Chen X., Cai K., Shen M., Chen X., Jiang L., Wang G. Inhibition of autophagy promotes the anti-tumor effect of metformin in oral squamous cell carcinoma. Cancers. 2022;14:4185. doi: 10.3390/cancers14174185.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cancers14174185</ArticleId><ArticleId IdType="pmc">PMC9454503</ArticleId><ArticleId IdType="pubmed">36077722</ArticleId></ArticleIdList></Reference><Reference><Citation>Gewalt T., Noh K.W., Meder L. The role of LIN28B in tumor progression and metastasis in solid tumor entities. Oncol. Res. 2023;31:101–115. doi: 10.32604/or.2023.028105.</Citation><ArticleIdList><ArticleId IdType="doi">10.32604/or.2023.028105</ArticleId><ArticleId IdType="pmc">PMC10208000</ArticleId><ArticleId IdType="pubmed">37304235</ArticleId></ArticleIdList></Reference><Reference><Citation>Lekka E., Kokanovic A., Mosole S., Civenni G., Schmidli S., Laski A., Ghidini A., Iyer P., Berk C., Behera A., et al. Pharmacological inhibition of Lin28 promotes ketogenesis and restores lipid homeostasis in models of non-alcoholic fatty liver disease. Nat. Commun. 2022;13:7940. doi: 10.1038/s41467-022-35481-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-35481-1</ArticleId><ArticleId IdType="pmc">PMC9792516</ArticleId><ArticleId IdType="pubmed">36572670</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen H., Sa G., Li L., He S., Wu T. In vitro and in vivo synergistic anti-tumor effect of LIN28 inhibitor and metformin in oral squamous cell carcinoma. Eur. J. Pharmacol. 2021;891:173757. doi: 10.1016/j.ejphar.2020.173757.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejphar.2020.173757</ArticleId><ArticleId IdType="pubmed">33249080</ArticleId></ArticleIdList></Reference><Reference><Citation>Alimoradi N., Firouzabadi N., Fatehi R. How metformin affects various malignancies by means of microRNAs: A brief review. Cancer Cell Int. 2021;21:207. doi: 10.1186/s12935-021-01921-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12935-021-01921-z</ArticleId><ArticleId IdType="pmc">PMC8045276</ArticleId><ArticleId IdType="pubmed">33849540</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu X., Xiong H., Chen W., Huang L., Mao T., Yang L., Wang C., Huang D., Wang Z., Yu J., et al. Metformin reduces the increased risk of oral squamous cell carcinoma recurrence in patients with type 2 diabetes mellitus: A cohort study with propensity score analyses. Surg. Oncol. 2020;35:453–459. doi: 10.1016/j.suronc.2020.09.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.suronc.2020.09.023</ArticleId><ArticleId IdType="pubmed">33065527</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang W.M., Yang S.S., Shao S.H., Nie H.Q., Zhang J., Su T. Metformin downregulates the expression of epidermal growth factor receptor independent of lowering blood glucose in oral squamous cell carcinoma. Front. Endocrinol. 2022;13:828608. doi: 10.3389/fendo.2022.828608.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fendo.2022.828608</ArticleId><ArticleId IdType="pmc">PMC8864766</ArticleId><ArticleId IdType="pubmed">35222283</ArticleId></ArticleIdList></Reference><Reference><Citation>Ben Sahra I., Laurent K., Loubat A., Giorgetti-Peraldi S., Colosetti P., Auberger P., Tanti J.F., Le Marchand-Brustel Y., Bost F. The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene. 2008;27:3576–3586. doi: 10.1038/sj.onc.1211024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.onc.1211024</ArticleId><ArticleId IdType="pubmed">18212742</ArticleId></ArticleIdList></Reference><Reference><Citation>Aljofan M., Riethmacher D. Anticancer activity of metformin: A systematic review of the literature. Future Sci. OA. 2019;5:FSO410. doi: 10.2144/fsoa-2019-0053.</Citation><ArticleIdList><ArticleId IdType="doi">10.2144/fsoa-2019-0053</ArticleId><ArticleId IdType="pmc">PMC6745597</ArticleId><ArticleId IdType="pubmed">31534778</ArticleId></ArticleIdList></Reference><Reference><Citation>He Y., Tai S., Deng M., Fan Z., Ping F., He L., Zhang C., Huang Y., Cheng B., Xia J. Metformin and 4SC-202 synergistically promote intrinsic cell apoptosis by accelerating ΔNp63 ubiquitination and degradation in oral squamous cell carcinoma. Cancer Med. 2019;8:3479–3490. doi: 10.1002/cam4.2206.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cam4.2206</ArticleId><ArticleId IdType="pmc">PMC6601594</ArticleId><ArticleId IdType="pubmed">31025540</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta P., Chandra S., Jha A.K., Khaitan T., Shukla A.K., Naik S.R. Increased vitamin B12 levels in patients with oral cancer. Indian J. Dent. Res. 2023;34:164–168. doi: 10.4103/ijdr.ijdr_1124_21.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/ijdr.ijdr_1124_21</ArticleId><ArticleId IdType="pubmed">37787205</ArticleId></ArticleIdList></Reference><Reference><Citation>Tiwari A., Kumar Singh R., Satone P.D., Meshram R.J. Metformin-induced vitamin B12 deficiency in patients with type-2 diabetes mellitus. Cureus. 2023;15:e47771. doi: 10.7759/cureus.47771.</Citation><ArticleIdList><ArticleId IdType="doi">10.7759/cureus.47771</ArticleId><ArticleId IdType="pmc">PMC10688235</ArticleId><ArticleId IdType="pubmed">38034222</ArticleId></ArticleIdList></Reference><Reference><Citation>Thewjitcharoen Y., Chongvoranond P., Nakasatien S., Krittiyawong S., Himathongkam T. Metformin-associated vitamin B12 deficiency: An underrecognized complication. JCEM Case Rep. 2024;2:luae029. doi: 10.1210/jcemcr/luae029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/jcemcr/luae029</ArticleId><ArticleId IdType="pmc">PMC11017106</ArticleId><ArticleId IdType="pubmed">38623534</ArticleId></ArticleIdList></Reference><Reference><Citation>Hans M., Malik P.K., Hans V.M., Chug A., Kumar M. Serum levels of various vitamins in periodontal health and disease—A cross sectional study. J. Oral Biol. Craniofac. Res. 2023;13:471–475. doi: 10.1016/j.jobcr.2023.05.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jobcr.2023.05.009</ArticleId><ArticleId IdType="pmc">PMC10230257</ArticleId><ArticleId IdType="pubmed">37266109</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie W., Li J., Kong C., Luo W., Zheng J., Zhou Y. Metformin-cimetidine drug interaction and risk of lactic acidosis in renal failure: A pharmacovigilance-pharmacokinetic appraisal. Diabetes Care. 2024;47:144–150. doi: 10.2337/dc23-1344.</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/dc23-1344</ArticleId><ArticleId IdType="pubmed">37948503</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuno H., Fujimaru T., Kadota N., Konishi K., Sekiguchi M., Watanabe K., Ito Y., Nagahama M., Taki F., Hifumi T., et al. Severe lactic acidosis with euglycemic diabetic ketoacidosis due to metformin overdose. CEN Case Rep. 2023;12:408–412. doi: 10.1007/s13730-023-00783-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13730-023-00783-w</ArticleId><ArticleId IdType="pmc">PMC10620342</ArticleId><ArticleId IdType="pubmed">36934381</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>